Swiss National Bank Portfolio holdings
The Swiss National Bank (SNB), founded in 1907 and headquartered in Zurich with an office in Bern, is Switzerland’s central bank, responsible for conducting monetary policy, issuing the Swiss franc, and ensuring price stability, while uniquely managing a massive investment portfolio. Unlike most central banks, the SNB is a joint-stock company with shares traded on the SIX Swiss Exchange, owned roughly 55% by public entities like cantons and 45% by private investors, yet it operates independently under federal oversight. It holds over $800 billion in foreign currency reserves as of late 2024—invested in global equities, bonds, and gold—to manage the franc’s value, famously intervening in markets to prevent excessive appreciation, as seen with the 2015 abandonment of the euro peg. Led by Chairman Thomas Jordan until his planned exit in September 2024, the SNB balances its dual role as a monetary authority and a significant global investor, influencing both Swiss and international financial stability.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$114M |
| 2 |
BKI
Black Knight, Inc. Common Stock
BKI
|
+$31.3M |
| 3 |
PARA
Paramount Global Class B
PARA
|
+$26.4M |
| 4 |
Tyler Technologies
TYL
|
+$25M |
| 5 |
Brown & Brown
BRO
|
+$18.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$249M |
| 2 |
CELG
Celgene Corp
CELG
|
+$231M |
| 3 |
Microsoft
MSFT
|
+$171M |
| 4 |
Alibaba
BABA
|
+$140M |
| 5 |
Amazon
AMZN
|
+$99.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.49% |
| 2 | Healthcare | 14.66% |
| 3 | Consumer Discretionary | 11.66% |
| 4 | Communication Services | 10.19% |
| 5 | Industrials | 9.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
EPAY
1226
DELISTED
Bottomline Technologies Inc
EPAY
| $4.5M | ﹤0.01% |
83,900
+2,000
| +2% | +$91K |
|
1227
SSR Mining
SSRM
$6.49B
| $4.48M | ﹤0.01% |
233,211
+3,600
| +2% | +$56K |
|
1228
Pediatrix Medical
MD
$2.14B
| $4.48M | ﹤0.01% |
161,200
-1,200
| -0.7% | -$30.1K |
|
1229
Ultragenyx Pharmaceutical
RARE
$2.6B
| $4.48M | ﹤0.01% |
104,852
+2,000
| +2% | +$82.5K |
|
|
AIMC
1230
DELISTED
Altra Industrial Motion Corp
AIMC
| $4.48M | ﹤0.01% |
123,600
+2,600
| +2% | +$82.6K |
|
|
ELME
1231
Elme Communities
ELME
$144M
| $4.47M | ﹤0.01% |
153,300
+3,000
| +2% | +$89.2K |
|
1232
Halozyme
HALO
$11.4B
| $4.47M | ﹤0.01% |
252,000
+5,500
| +2% | +$95.3K |
|
|
CADE
1233
DELISTED
Cadence Bancorporation
CADE
| $4.47M | ﹤0.01% |
246,305
+4,500
| +2% | +$75.2K |
|
1234
Albany International
AIN
$1.82B
| $4.46M | ﹤0.01% |
58,800
+4,300
| +8% | +$357K |
|
|
AAT
1235
American Assets Trust
AAT
$1.41B
| $4.46M | ﹤0.01% |
97,200
+5,200
| +6% | +$243K |
|
1236
Rapid7
RPD
$929M
| $4.45M | ﹤0.01% |
79,400
+2,400
| +3% | +$125K |
|
1237
Urban Edge Properties
UE
$2.78B
| $4.45M | ﹤0.01% |
231,909
+5,300
| +2% | +$107K |
|
1238
Rogers Corp
ROG
$2.46B
| $4.43M | ﹤0.01% |
35,500
+600
| +2% | +$81.1K |
|
|
BOLD
1239
DELISTED
Audentes Therapeutics, Inc
BOLD
| $4.42M | ﹤0.01% |
73,900
+3,400
| +5% | +$128K |
|
|
ALLK
1240
DELISTED
Allakos
ALLK
| $4.42M | ﹤0.01% |
46,300
+1,500
| +3% | +$132K |
|
1241
LivePerson
LPSN
$35.9M
| $4.41M | ﹤0.01% |
7,947
+220
| +3% | +$126K |
|
1242
Globant
GLOB
$1.77B
| $4.41M | ﹤0.01% |
41,556
-30,600
| -42% | -$3.05M |
|
1243
The Ensign Group
ENSG
$10.6B
| $4.41M | ﹤0.01% |
97,100
-4,241
| -4% | -$179K |
|
1244
First Bancorp
FBP
$4.49B
| $4.41M | ﹤0.01% |
416,000
+7,700
| +2% | +$80.4K |
|
|
GTLS
1245
DELISTED
Chart Industries
GTLS
| $4.39M | ﹤0.01% |
65,100
+2,200
| +3% | +$129K |
|
1246
Liberty Latin America Class C
LILAK
$1.65B
| $4.39M | ﹤0.01% |
263,546
+4,556
| +2% | +$70.5K |
|
1247
Sprouts Farmers Market
SFM
$7.71B
| $4.37M | ﹤0.01% |
226,050
+4,600
| +2% | +$89.1K |
|
1248
Cannae Holdings
CNNE
$675M
| $4.37M | ﹤0.01% |
117,594
+2,100
| +2% | +$69K |
|
|
ARQL
1249
DELISTED
Arqule Inc
ARQL
| $4.37M | ﹤0.01% |
218,700
+44,500
| +26% | +$516K |
|
1250
Nu Skin
NUS
$236M
| $4.36M | ﹤0.01% |
106,300
+1,800
| +2% | +$73.5K |
|
Similar funds
Swiss National Bank's Q4 2019 Portfolio in Review
As of Q4 2019, Swiss National Bank held 2,602 positions worth $97.5B, up 3.6% from $94.1B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Swiss National Bank withdrew a net $3.98B in Q4 2019, closing 96 positions and reducing 725 holdings. Its most notable exit was Celgene Corp, an estimated $231M position sold in full.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 20% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Swiss National Bank opened a new position in Match Group worth $14.7M.
- Swiss National Bank's largest Q4 2019 buy was Match Group: 179,200 shares worth $14.7M.
- Swiss National Bank added most to Bristol-Myers Squibb in Q4 2019, an estimated $114M increase.
- Swiss National Bank's biggest Q4 2019 reduction was Apple, cutting an estimated $249M.
- Swiss National Bank fully exited Celgene Corp in Q4 2019, selling an estimated $231M.
- Swiss National Bank's ten largest holdings make up 19% of its $97.5B portfolio in Q4 2019.
- Swiss National Bank opened 82 new positions and closed 96 in Q4 2019.
- Swiss National Bank's portfolio value rose 3.6% quarter-over-quarter to $97.5B.
Based on Swiss National Bank's 13F filing for Q4 2019, filed 6 Feb 2020.